Metffil VG 2 Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 2 mg, Metformin 500 mg, and Voglibose 0.2 mg. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestines, effectively reducing postprandial hyperglycemia. The sustained-release formulation ensures prolonged therapeutic effects, promoting better patient compliance through reduced dosing frequency. Metffil VG 2 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy with any of its components. It is essential to monitor blood glucose levels regularly and adjust the dosage based on glycemic response. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in individuals with diabetic ketoacidosis, severe infections, or hypersensitivity to any component. This combination therapy offers a multifaceted approach to glycemic management by targeting different pathophysiological mechanisms of type 2 diabetes.